Observation used increasingly in younger men with prostate cancer

This article originally appeared here.
Observation used increasingly in younger men with prostate cancer
Observation used increasingly in younger men with prostate cancer

(HealthDay News) -- Observation is increasingly being used among men with low-risk prostate cancer who are young and healthy enough for treatment, according to a study published in the March issue of The Journal of Urology.

Chad R. Ritch, M.D., M.B.A., from the University of Miami, and colleagues examined the temporal trend in observation of clinically localized prostate cancer in men who were young and healthy enough to undergo treatment. Data were included from the Surveillance, Epidemiology, and End Results-Medicare Database for 66,499 men with localized prostate cancer from 2004 to 2009. A predictive model of observation was developed after adjustment for diagnosis year, age, risk, and comorbidity.

The researchers found that observation was performed in 18 percent of men overall, and increased over time from 17 to 20 percent. Among men with low-risk disease, there was a marked increase in observation, from 18 percent in 2004 to 29 percent in 2009. The odds of undergoing observation were two-fold higher among men aged 66 to 69 years with low-risk disease and no comorbidities (odds ratio, 2.12). Independent predictors of observation included age, risk group, comorbidity, and race (all P < 0.001), as well as year of diagnosis.

"This suggests growing acceptance of surveillance in this group of patients," the authors write.

Two authors disclosed financial ties to the pharmaceutical and medical device industries.

Full Text (subscription or payment may be required)

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs